Trial Profile
BAX 326 (Recombinant Factor IX): A Phase 3 Prospective, Multicenter Study Evaluating Efficacy and Safety in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level lt;= 2%) Hemophilia B Undergoing Surgical or Other Invasive Procedures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nonacog alfa (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Baxalta; Baxter Healthcare Corporation; Shire
- 25 Jun 2014 New trial record